<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>PF942: CD19 Expression & CAR-T Outcomes in B-Cell Lymphoma</title>
    <link rel="stylesheet" href="abstract_styles.css">
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">

    <meta name="study:id" content="de-bernardis-cd19-cart">
    <meta name="study:title" content="PF942: Impact of pre-infusion CD19 expression on CAR T-cell expansion and clinical outcomes in R/R B-cell lymphoma">
    <meta name="study:fileName" content="Abstracts/DeBernardis_EHA2025_PF942.html">
    <meta name="study:cancerTypes" content="LBCL, FL, B-NHL">
    <meta name="study:lineOfTherapy" content="3L+">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="CAR-T cells, Axi-cel, Tisa-cel, Brexu-cel">
</head>

<body class="abstract-page-body">

    <div class="slide-container">
        <div class="visual-abstract-container">
            <h3 class="visual-abstract-title">Visual Summary: CD19 Expression & CAR-T Outcomes in R/R B-Cell Lymphoma</h3>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg fill="#0A2F5C" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M16 11c1.66 0 2.99-1.34 2.99-3S17.66 5 16 5c-1.66 0-3 1.34-3 3s1.34 3 3 3zm-8 0c1.66 0 2.99-1.34 2.99-3S9.66 5 8 5C6.34 5 5 6.34 5 8s1.34 3 3 3zm0 2c-2.33 0-7 1.17-7 3.5V19h14v-2.5c0-2.33-4.67-3.5-7-3.5zm8 0c-.29 0-.62.02-.97.05 1.16.84 1.97 1.97 1.97 3.45V19h6v-2.5c0-2.33-4.67-3.5-7-3.5z"/></svg>
                    <h4>Population & Aim</h4>
                    <p><b>Population:</b> N=103 (59 evaluable) with R/R B-Cell Lymphoma (LBCL, FL, MCL)<br><b>Aim:</b> Correlate pre-infusion CD19 levels with CAR-T expansion & outcomes.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg fill="#009B9E" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path d="M372.6 128.3L287.4 43.1a32.07 32.07 0 00-45.3 0l-85.2 85.2c-12.5 12.5-12.5 32.8 0 45.3l85.2 85.2c12.5 12.5 32.8 12.5 45.3 0l85.2-85.2c12.5-12.5 12.5-32.7 0-45.3zm-128 128l-85.2-85.2c-12.5-12.5-32.8-12.5-45.3 0l-85.2 85.2c-12.5 12.5-12.5 32.8 0 45.3l85.2 85.2c12.5 12.5 32.8 12.5 45.3 0l85.2-85.2c12.5-12.5 12.5-32.8 0-45.3zm128 0l-85.2-85.2c-12.5-12.5-32.8-12.5-45.3 0l-85.2 85.2c-12.5 12.5-12.5 32.8 0 45.3l85.2 85.2c12.5 12.5 32.8 12.5 45.3 0l85.2-85.2c12.5-12.5 12.5-32.8 0-45.3zM244.6 383.7L159.4 469a32.07 32.07 0 01-45.3 0l-85.2-85.2c-12.5-12.5-12.5-32.8 0-45.3l85.2-85.2c12.5-12.5 32.8-12.5 45.3 0l85.2 85.2c12.5 12.4 12.5 32.7 0 45.2z"/></svg>
                    <h4>Intervention / Method</h4>
                    <p><b>Commercial CAR-T Cell Therapy</b><br>(Axi-cel, Tisa-cel, Brexu-cel) via retrospective analysis.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg fill="#F37021" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 13h2v-2H3v2zm0 4h2v-2H3v2zm0-8h2V7H3v2zm4 4h14v-2H7v2zm0 4h14v-2H7v2zm0-10v2h14V7H7z"/></svg>
                    <h4>Key Efficacy Result</h4>
                    <p>Day +30 Response (N=59)</p>
                    <span class="highlight-value">ORR: 89.8%</span>
                    <p>CRR/CMR: 72.9%</p>
                </div>
                <div class="visual-abstract-item">
                     <svg fill="#0A2F5C" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 2C6.48 2 2 6.48 2 12s4.48 10 10 10 10-4.48 10-10S17.52 2 12 2zm-2 15l-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8l-9 9z"/></svg>
                    <h4>Conclusion</h4>
                    <p>Pre-infusion CD19 expression level did not significantly impact CAR T-cell expansion or clinical outcomes in this cohort.</p>
                </div>
            </div>
        </div>

        <h1 class="abstract-header-title">PF942: Impact of pre-infusion CD19 expression on CAR T-cell expansion and clinical outcomes in R/R B-cell lymphoma</h1>
        <p class="abstract-sub-header">De Bernardis D, et al.</p>
        <p class="abstract-meta-info">Poster #PF942 presented at the European Hematology Association (EHA) Congress, June 12-15, 2025, Milan, Italy.</p>

        <div class="abstract-card">
            <h2 class="abstract-section-title">Background</h2>
            <p>Chimeric Antigen Receptor (CAR) T-cell therapy is a standard of care for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), with its efficacy dependent on adequate CAR T-cell expansion and persistence. Antigen escape, particularly the loss of CD19, is a recognized mechanism of resistance. However, the influence of the pre-infusion level of CD19 expression on lymphoma cells is not fully understood, with conflicting data on its correlation with CAR T-cell kinetics and clinical response.</p>
        </div>

        <div class="abstract-card">
            <h2 class="abstract-section-title">Aims</h2>
            <p>This retrospective, single-center study aimed to evaluate the correlation between pre-infusion CD19 expression levels on malignant B-cells and both CAR T-cell expansion kinetics and clinical outcomes in patients with R/R B-cell lymphomas treated with commercial CAR T-cell products.</p>
        </div>

        <div class="abstract-card">
            <h2 class="abstract-section-title">Methods & Study Design</h2>
            <ul class="list-disc">
                <li><b>Study Design:</b> A retrospective analysis was conducted on 103 patients with R/R B-cell malignancies (including LBCL, Follicular Lymphoma [FL], and Mantle Cell Lymphoma [MCL]) treated with commercial CAR T-cell products (Axi-cel, Tisa-cel, Brexu-cel) between May 2019 and December 2023.</li>
                <li><b>CD19 Assessment:</b> CD19 expression was assessed by flow cytometry on pre-leukapheresis tissue samples. Patients were considered CD19-positive if >20% of malignant cells expressed CD19. Data was available for 59 patients.</li>
                <li><b>Endpoints:</b> The primary endpoint was the correlation between CD19 expression levels and in-vivo CAR T-cell expansion kinetics. Secondary endpoints included clinical outcomes such as overall response rate (ORR) and complete metabolic response (CMR).</li>
            </ul>
             <div class="study-design-schema">
                <div class="schema-title">Study Workflow</div>
                <div class="schema-phases">
                    <div class="schema-phase-group">
                        <div class="schema-enrollment">Patients Screened<br><b>(N=103)</b></div>
                        <div class="schema-arrow">→</div>
                        <div class="schema-phase"><strong>Sample Collection</strong><span>Pre-leukapheresis tissue biopsy</span></div>
                        <div class="schema-arrow">→</div>
                         <div class="schema-phase"><strong>CD19 Analysis (N=59)</strong><span>Flow cytometry to quantify %CD19+ cells</span></div>
                        <div class="schema-arrow">→</div>
                        <div class="schema-phase"><strong>CAR T-Cell Infusion</strong><span>Axi-cel, Tisa-cel, or Brexu-cel</span></div>
                    </div>
                     <div class="schema-arrow-down">↓</div>
                    <div class="schema-assessment-points">
                        <span>CAR-T Kinetics Assessment</span>
                        <span>Clinical Outcome Assessment (Day +30)</span>
                    </div>
                </div>
            </div>
        </div>

        <div class="abstract-card">
            <h2 class="abstract-section-title">Results</h2>
            
            <h3 class="abstract-sub-section-title">Patient Characteristics & CD19 Expression</h3>
            <p>Of 103 patients treated, 59 had available pre-infusion CD19 expression data. The distribution of CD19 expression among these 59 patients is shown below.</p>
            <div class="table-container">
                <table>
                    <thead>
                        <tr>
                            <th>CD19 Expression Level (% of malignant cells)</th>
                            <th>Number of Patients (N=59)</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>< 20% (CD19-Negative)</td>
                            <td>7</td>
                        </tr>
                        <tr>
                            <td>20 - 40%</td>
                            <td>4</td>
                        </tr>
                        <tr>
                            <td>41 - 60%</td>
                            <td>5</td>
                        </tr>
                         <tr>
                            <td>61 - 80%</td>
                            <td>8</td>
                        </tr>
                        <tr>
                            <td>> 80%</td>
                            <td>35</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <h3 class="abstract-sub-section-title">Efficacy</h3>
            <p>Clinical response was evaluated at day +30 post-infusion for the 59 patients with available CD19 data. The Overall Response Rate (ORR) was 89.8%.</p>
             <div class="chart-container" id="response-chart-container">
                <svg id="response-chart" width="350" height="350"></svg>
                <div class="legend">
                    <div class="legend-item"><span class="legend-color-box" style="background-color: var(--sobi-teal);"></span>Complete Response (CR)</div>
                    <div class="legend-item"><span class="legend-color-box" style="background-color: var(--sobi-yellow);"></span>Partial Response (PR)</div>
                    <div class="legend-item"><span class="legend-color-box" style="background-color: var(--sobi-orange);"></span>Stable Disease (SD)</div>
                    <div class="legend-item"><span class="legend-color-box" style="background-color: var(--sobi-medium-gray-text);"></span>Progressive Disease (PD)</div>
                </div>
            </div>
            <div class="footnote-text">
                <p>Response data extracted from poster figure. N=59 evaluable patients. CR: 43 (72.9%), PR: 10 (16.9%), SD: 2 (3.4%), PD: 4 (6.8%). The abstract text states a Complete Metabolic Response (CMR) rate of 66%, while the chart data indicates a CR rate of 72.9% (43/59).</p>
                <p>Relapse with CD19-positive disease was observed in 8 patients, with a median time to relapse of 9 months.</p>
            </div>
            
            <h3 class="abstract-sub-section-title">CAR T-Cell Expansion Kinetics</h3>
            <p>Analysis of CAR T-cell expansion kinetics in peripheral blood showed no statistically significant difference between patients with CD19-positive (>20%) and CD19-negative (<20%) tumors. Furthermore, when stratified by different levels of CD19 expression, there was still no clear correlation with the magnitude or timing of CAR T-cell expansion, suggesting that even low levels of target antigen are sufficient to trigger an effective initial expansion.</p>
            <div style="display: flex; justify-content: space-around; flex-wrap: wrap; gap: 1rem; margin-top: 1rem;">
                <div class="zoomable-image-container">
                    <img src="https://i.imgur.com/gK9qQd4.png" alt="Chart showing CAR T-cell expansion in CD19-positive vs CD19-negative patients. Both groups show similar expansion peaks and kinetics, with no significant difference observed." class="zoomable-image" style="max-width: 400px; border: 1px solid #ccc; border-radius: 4px;">
                </div>
                 <div class="zoomable-image-container">
                    <img src="https://i.imgur.com/uW6J9nJ.png" alt="Chart showing CAR T-cell expansion stratified by different CD19 expression levels (<40%, 40-80%, >80%). No clear correlation is visible between the level of CD19 expression and the expansion kinetics." class="zoomable-image" style="max-width: 400px; border: 1px solid #ccc; border-radius: 4px;">
                </div>
            </div>
        </div>

        <div class="abstract-card">
            <h2 class="abstract-section-title">Safety</h2>
            <p>Safety data were not a focus of this analysis and were not presented in the poster.</p>
        </div>

        <div class="abstract-card">
            <h2 class="abstract-section-title">Conclusions and Perspectives</h2>
            <ul class="list-disc">
                <li>In this retrospective analysis, the pre-infusion expression level of CD19 on malignant cells did not significantly correlate with in-vivo CAR T-cell expansion or clinical outcomes in patients with R/R B-cell lymphomas.</li>
                <li>The data suggest that even a low level of CD19 expression may be sufficient to initiate CAR T-cell activation and expansion, and the conventional >20% cutoff for defining "positivity" may not be the optimal predictive threshold.</li>
                <li>These findings challenge the role of pre-infusion CD19 expression level as a standalone predictive biomarker. A more comprehensive evaluation of the tumor and its microenvironment may be necessary to better stratify patients for CAR T-cell therapy.</li>
            </ul>
        </div>
        
        <div class="abstract-card">
             <h2 class="abstract-section-title">Reference
                <button id="copyReferenceBtn" class="copy-reference-button">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-4 h-4 mr-1.5"><path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.12A1.5 1.5 0 0117 6.622V12.5a1.5 1.5 0 01-1.5 1.5h-1A1.5 1.5 0 0013 15.5v1A1.5 1.5 0 0111.5 18h-8A1.5 1.5 0 012 16.5v-11A1.5 1.5 0 013.5 4H7V3.5zM8.5 4H7v9.5A1.5 1.5 0 008.5 15h4.5V7.121a1 1 0 00-.293-.707L9.207 2.91A1 1 0 008.5 2.5V4z"></path></svg>
                    Copy
                </button>
            </h2>
            <div class="reference-section">
                <p id="referenceSectionContent">De Bernardis D, et al. Impact of pre-infusion cd19 expression on CAR T-cell expansion and clinical outcomes in r/r b-cell lymphoma. Abstract #PF942 presented at the European Hematology Association (EHA) Congress. 12–15 June 2025, Milan, Italy.</p>
            </div>
        </div>

        <footer class="abstract-footer-info">
            <p>This is a simplified summary of a scientific abstract. For complete details, please refer to the original publication.</p>
            <p>Generated by Abstractifier on Tue Jun 25 2024</p>
        </footer>

    </div>

    <script>
        // D3.js script for the stacked bar chart
        const data = [
            { response: 'CR', value: 72.9, n: 43, color: 'var(--sobi-teal)' },
            { response: 'PR', value: 16.9, n: 10, color: 'var(--sobi-yellow)' },
            { response: 'SD', value: 3.4, n: 2, color: 'var(--sobi-orange)' },
            { response: 'PD', value: 6.8, n: 4, color: 'var(--sobi-medium-gray-text)' }
        ];

        const svg = d3.select("#response-chart");
        const margin = { top: 40, right: 30, bottom: 40, left: 50 };
        const width = +svg.attr("width") - margin.left - margin.right;
        const height = +svg.attr("height") - margin.top - margin.bottom;

        const g = svg.append("g").attr("transform", `translate(${margin.left},${margin.top})`);

        const x = d3.scaleBand()
            .domain(["Response"])
            .range([0, width])
            .padding(0.6);

        const y = d3.scaleLinear()
            .domain([0, 100])
            .range([height, 0]);

        const stack = d3.stack()
            .keys(data.map(d => d.response))
            .value((d, key) => d[0][key]);

        const seriesData = [{ "Response": Object.fromEntries(data.map(d => [d.response, d.value])) }];
        const stackedData = stack(seriesData);

        g.append("g")
            .attr("class", "x-axis")
            .attr("transform", `translate(0,${height})`)
            .call(d3.axisBottom(x).tickSize(0).tickPadding(10))
            .select(".domain").remove();

        g.append("g")
            .attr("class", "y-axis axis-text")
            .call(d3.axisLeft(y).ticks(5).tickFormat(d => d + "%"))
            .select(".domain").remove();
            
        g.selectAll(".tick line").remove();

        g.append("g")
            .selectAll("g")
            .data(stackedData)
            .join("g")
            .attr("fill", (d, i) => data[i].color)
            .selectAll("rect")
            .data(d => d)
            .join("rect")
            .attr("x", d => x("Response"))
            .attr("y", d => y(d[1]))
            .attr("height", d => y(d[0]) - y(d[1]))
            .attr("width", x.bandwidth());
            
        // Add ORR label
        const orrValue = data.find(d => d.response === 'CR').value + data.find(d => d.response === 'PR').value;
        g.append("text")
          .attr("x", x("Response") + x.bandwidth() / 2)
          .attr("y", y(orrValue) - 10) // Position above the PR stack
          .attr("text-anchor", "middle")
          .attr("font-weight", "bold")
          .attr("fill", "var(--sobi-dark-blue)")
          .text(`ORR: ${orrValue.toFixed(1)}%`);
          
        // Add Title
        svg.append("text")
            .attr("x", (width + margin.left + margin.right) / 2)
            .attr("y", margin.top / 2 + 5)
            .attr("text-anchor", "middle")
            .style("font-size", "1rem")
            .style("font-weight", "600")
            .style("fill", "var(--sobi-dark-blue)")
            .text("Response at Day +30 (N=59)");

    </script>
     <script src="../abstract_features.js"></script>
</body>
</html>